In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor

Blood

Volumn 101, Issue 4, 2003, Pages 1359-1366

  Waddington, Simon N ^a   Buckley, Suzanne M K ^b   Nivsarkar, Megha ^b   Jezzard, Sarah ^b   Schneider, Holm ^b   Dahse, Thomas ^b   Kemball Cook, Geoff ^b   Miah, Maznu ^b   Tucker, Nick ^b   Dallman, Margaret J ^b   Themis, Mike ^b   Coutelle, Charles ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 9; RECOMBINANT PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; FETUS; GENE AMPLIFICATION; GENE EXPRESSION; GENE TRANSFER; IMMUNITY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; TRANSGENE;

EID: 0037441596     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0779     Document Type: Article

References (26)

1. Herzog RW, Fields PA, Arruda VR, et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther. 2002;13:1281-1291.
2. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost. 2000;26:179-188.
3. Warrier I. Factor IX antibody and immune tolerance. Vox Sang. 1999;77(suppl 1):70-71.
4. Goudemand J. Pharmaco-economic aspects of inhibitor treatment. Eur J Haematol Suppl. 1998;63:24-27.
5. Fang B, Eisensmith RC, Wang H, et al. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther. 1995;6:1039-1044.
6. Hagstrom JN, Couto LB, Scallan C, et al. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter. Blood. 2000;95:2536-2542.
7. Fields PA, Armstrong E, Hagstrom JN, et al. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice. Gene Ther. 2001;8:354-361.
8. Michou AI, Santoro L, Christ M, Julliard V, Pavirani A, Mehtali M. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther. 1997;4:473-482.
9. Wang L, Zoppe M, Hackeng TM, Griffin JH, Lee KF, Verma IM. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A. 1997;94:11563-11566.
10. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A. 1995;92:1401-1405.
11. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999;5:56-63.
12. Chao H, Samulski, R, Bellinger D, Monahan P, Nichols T, Walsh C. Persistent expression of canine factor IX in hemophilia B canines. Gene Ther. 1999;6:1695-1704.
13. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. 1999;5:64-70.
14. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liverdirected gene therapy. Blood. 2002;99:2670-2676.
15. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24:257-261.
16. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature. 1953;172:603-606.
17. Lipshutz GS, Flebbe-Rehwaldt L, Gaensler KM. Reexpression following readministration of an adenoviral vector in adult mice after initial in utero adenoviral administration. Mol Ther. 2000;2:374-380.
18. Lipshutz GS, Gruber CA, Cao Y, Hardy J, Contag CH, Gaensler KM. In utero delivery of adenoassociated viral vectors: intraperitoneal gene transfer produces long-term expression. Mol Ther. 2001;3:284-292.
19. Walter J, You Q, Hagstrom JN, Sands M, High KA. Successful expression of human factor IX following repeat administration of adenoviral vector in mice. Proc Natl Acad Sci U S A. 1996;93:3056-3061.
20. Schneider H, Adebakin S, Themis M, Cook T, Pavirani A, Coutelle C. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B. J Gene Med. 1999;1:424-432.
21. Schneider H, Mühle C, Douar AM, et al. Sustained delivery of therapeutic concentrations of human clotting factor IX - a comparison of adenoviral and AAV vectors administered in utero. J Gene Med. 2002;4:46-53.
22. Douar AM, Adebakin S, Themis M, Pavirani A, Cook T, Coutelle C. Foetal gene delivery in mice by intra-amniotic administration of retroviral producer cells and adenovirus. Gene Ther. 1997;4:883-890.
23. Schachtner S, Buck C, Bergelson J, Baldwin H. Temporally regulated expression patterns following in utero adenovirus-mediated gene transfer. Gene Ther. 1999;6:1249-1257.
24. Themis M, Schneider H, Kiserud T, et al. Successful expression of beta-galactosidase and factor IX transgenes in fetal and neonatal sheep after ultrasound-guided percutaneous adenovirus vector administration into the umbilical vein. Gene Ther. 1999;6:1239-1248.
25. Tripathy SK, Goldwasser E, Lu MM, Barr E, Leiden JM. Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replicationdefective adenovirus. Proc Natl Acad Sci U S A. 1994;91:11557-11561.
26. Stratford-Perricaudet LD, Levrero M, Chasse JF, Perricaudet M, Briand P. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther. 1990;1:241-256.